Dishman Carbogen Amcis Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/wt0dmvc2atcu22vspd1jj1qw.pdf

Key Takeaways


Bavla Facility: The Regulatory Catalyst

Paolo Armanino: "Needless to say that there was a great enthusiasm honestly by the customer. So the old customer, they are really very happy about this news, especially with EDQM, but also the PMDA because the Bavla today is approved by all the major authorities worldwide."

French Facility: Delayed Start, Gradual Ramp

Pascal Villemagne: "We discovered a few things that shifting that we had to fix before we started. So that was the reasons why we had to postpone the startup for a few weeks."

Segment & Margin Performance


ADC & Other Growth Drivers

Pascal Villemagne: "Unfortunately, this information could be related to volumes and that kind of information, we are binding with our customer to confidentiality. What I can tell you is it's going to have a major increment on our top line revenues with several kind of mediums in the future."

Operational Improvements & Internal Collaboration

Sanjay Majmudar: "It looks like, I would believe, one of the best facilities in India today in terms of the technical as well as the overall qualifications."

Guidance & Commitments

CommitmentSpecificsTimeline
EDQM green lightFinal certification following successful audit with only procedural recommendations~6 weeks from reply submission (authority timeline, not company-controlled)
French facility breakevenApproach breakeven on the new facilityBy end of current financial year (FY24)
French facility revenueAt least EUR2 crore revenue, slightly positive EBITDAFY25
Bavla facility revenueINR400–450 crores of revenueFY25
India H2 catch-upPositive consolidated margins as more shipments go outH2 FY24
ADC revenue startFirst campaign with Japanese customer begins; assets generating revenueJanuary 2024 (Q4 FY24)
Free cash flowFree cash flow generation begins as capex cycle ends and returns commenceFY25
EBITDA margin target25% EBITDA margin, with increase beginning next fiscal yearFY26

Key Metrics

MetricQ2 FY24
Revenue from operations₹587 cr, vs ₹614 cr in Q2 FY23
EBITDA₹63 cr, margin at ~10.5%
Employee expenses increase₹32 cr YoY, ~₹30 cr from Swiss franc forex fluctuation
Finance cost₹27.5 cr, vs ₹20 cr in Q2 FY23
Carbogen Amcis CRAM revenue₹437 cr, flattish vs Q2 FY23
Carbogen Amcis Group H1 FY24 revenue~₹1,000 cr, +24.5% YoY
Cholesterol and vitamin D analogues revenue₹87 cr, +35% YoY from ₹64 cr
Cholesterol and vitamin D analogues H1 FY24 revenue₹180 cr, +40% YoY from ₹128 cr
Carbogen Amcis Group EBITDA margin12.2%, vs 14.6% in Q2 FY23
Cholesterol and vitamin D analogues margin~10%, vs 18% in Q2 FY23
Full-year capex guidance~₹3 cr, with ₹1.7 cr spent in H1
French facility FY25 revenue targetAt least €2 cr
French facility current-year revenue forecastClose to €8 million, maybe a little more
CWIP₹900 cr, expected to drop to not more than ₹200 cr by March (per an analyst's math)
EBITDA margin target of 25%FY '26